ISIS-APOCIIIRx: Phase II data

A double-blind Phase II trial in 11 Type II diabetics with high triglyceride levels (200-500 mg/dL) showed that once-weekly 300 mg subcutaneous ISIS-APOCIIIRx met the primary endpoint of reducing APOC...